|
|
Volumn 48, Issue 6, 2009, Pages 704-
|
|
Unifying abbreviations for biologics in rheumatology - Does the idea hold promise?
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ABATACEPT;
ADALIMUMAB;
ALEFACEPT;
ALEMTUZUMAB;
ANTIRHEUMATIC AGENT;
ATLIZUMAB;
BAMINERCEPT;
BASILIXIMAB;
BELIMUMAB;
BEVACIZUMAB;
CANAKINUMAB;
CERTOLIZUMAB;
DACLIZUMAB;
DENOSUMAB;
ECULIZUMAB;
EFALIZUMAB;
EPRATUZUMAB;
ETANERCEPT;
GOLIMUMAB;
INFLIXIMAB;
NATALIZUMAB;
OCRELIZUMAB;
OFATUMUMAB;
ONERCEPT;
RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;
RITUXIMAB;
TANEZUMAB;
UNCLASSIFIED DRUG;
USTEKINUMAB;
DRUG RESEARCH;
HUMAN;
INFORMATION PROCESSING;
LETTER;
NOMENCLATURE;
PRIORITY JOURNAL;
RHEUMATIC DISEASE;
RHEUMATOLOGY;
SYMPOSIUM;
ABBREVIATIONS AS TOPIC;
BIOLOGICAL PRODUCTS;
HUMANS;
RHEUMATOLOGY;
|
|
EID: 65849492418
PISSN: 14620324
EISSN: 14620332
Source Type: Journal
DOI: 10.1093/rheumatology/kep042 Document Type: Letter |
|
Times cited : (2)
|
|
References (1)
|
